echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > A total of more than 3 billion US dollars: Roche enters allogeneic T cell therapy

    A total of more than 3 billion US dollars: Roche enters allogeneic T cell therapy

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 7, Roche’s subsidiary Genentech and Adaptimmune reached a cooperation to jointly develop allogeneic T cell therapies to treat multiple tumor indications, with a total transaction amount of up to 3 billion US dollars


    Adaptimmune stock price trend

    From: Yahoo Finance

    This partnership covers for up to five undisclosed cancer target share "stock type" (Off-the-shelf) cell therapy research and development and the new allogeneic personalized cell therapy platform development


    "Off-the-shelf" Cell Therapy Allogeneic Personalized Cell Therapy Platform

    After the transaction is concluded, Adaptimmune will receive an upfront payment of US$150 million and an additional US$150 million in payments over the next five years, as well as development, regulatory and commercial milestone payments and mid-single to low double-digit net sales The total price of tiered royalties may exceed 3 billion US dollars ; in addition, Adaptimmune has the option of 50/50 US profits/components of "off-the-shelf" products.


    The total price may exceed 3 billion U.


    Dr.


    Not only Roche, this company has also reached cooperation with many large pharmaceutical companies


    Not only Roche, this company has also reached cooperation with many large pharmaceutical companies


    Adaptimmune's clinical stage pipeline

    Adaptimmune's early clinical pipeline

    The above pictures are from: Adaptimmune official website

    Compared with CAR-T therapy, TCR-T has taken the lead in achieving breakthroughs in solid tumors


    Compared with CAR-T therapy, TCR-T has taken the lead in achieving breakthroughs in solid tumors


    Edit edit : add one

    PR draft docking : WeChat insightxb

    PR draft docking PR draft docking : WeChat insightxb

    Contribution : WeChat insightxb; Email insight@dxy.


    Submission Submission : micro-channel insightxb; mailbox insight@dxy.
    cn
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.